CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF264 (ImmuneEditome ID:9422)

1. Gene summary of enriched editing regions for ZNF264

check button Gene summary
Gene informationGene symbol

ZNF264

Gene ID

9422

GeneSynonyms-
GeneCytomap

19q13.43

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 264
GeneModificationdate20230518
UniprotIDO43296;M0R146;M0QXF3;M0QZJ4;M0QZT5
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:57214334-57214663:+ENST00000263095.9ENSG00000083844.9ZNF264UTR3AluJb,L1MDachr19:57214334-57214663:+.alignment
chr19:57216048-57216321:+ENST00000263095.9ENSG00000083844.9ZNF264UTR3AluSz6,L1MDachr19:57216048-57216321:+.alignment
chr19:57217394-57218014:+ENST00000263095.9ENSG00000083844.9ZNF264UTR3L1MDa,AluSg,AluSg7chr19:57217394-57218014:+.alignment
chr19:57220633-57222346:+ENST00000263095.9ENSG00000083844.9ZNF264UTR3AluSz,AluSx,AluSx1,MER68chr19:57220633-57222346:+.alignment


Top

2. Tumor-specific enriched editing regions for ZNF264


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:57220633-57222346:+BRCAEER3.2540e-04image
ENSG00000083844.9,ZNF264BRCAEAG8.2341e-03image
ENSG00000083844.9,ZNF264COADEAG1.6125e-02image
chr19:57220633-57222346:+HNSCEER4.0757e-07image
ENSG00000083844.9,ZNF264HNSCEAG2.4615e-03image
chr19:57220633-57222346:+KIRCEER4.2486e-03image
chr19:57214334-57214663:+KIRPEER3.0481e-02image
chr19:57216048-57216321:+KIRPEER2.4019e-02image
chr19:57220633-57222346:+KIRPEER7.3131e-03image
ENSG00000083844.9,ZNF264KIRPEAG3.4515e-03image
chr19:57220633-57222346:+LUADEER3.4966e-02image
chr19:57214334-57214663:+LUSCEER1.4020e-03image
chr19:57220633-57222346:+LUSCEER5.7138e-06image
ENSG00000083844.9,ZNF264LUSCEAG1.0267e-04image
ENSG00000083844.9,ZNF264PRADEAG1.0673e-03image
ENSG00000083844.9,ZNF264THCAEAG3.3541e-03image
chr19:57220633-57222346:+UCECEER1.5146e-09image
ENSG00000083844.9,ZNF264UCECEAG2.3441e-10image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000083844.9,ZNF264ACCPathEAG1.5945e-022.7287e-02-0.2639image
chr19:57220633-57222346:+ACCPathEER3.2552e-021.5930e-02-0.2914image
ENSG00000083844.9,ZNF264KIRCPathEAG1.6782e-021.8379e-030.1360image
chr19:57220633-57222346:+LUSCPathEER4.3132e-023.6164e-020.1067image
chr19:57214334-57214663:+LUSCPathEER2.5526e-032.5223e-020.1255image
ENSG00000083844.9,ZNF264THCAPathEAG1.3820e-066.8273e-050.1771image
chr19:57220633-57222346:+THCAPathEER9.1676e-031.2466e-020.1122image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000083844.9,ZNF264STADEAG8.2011e-031.8350e-033.2953e+02image

Top

3. Enriched editing regions and immune related genes for ZNF264


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:57220633-57222346:+UCECEERENSG00000000419,DPM10.31971.2337e-024.9513e-070.4006imageNELAVL1;U2AF2;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr19:57220633-57222346:+UCECEERENSG00000115233,PSMD140.29362.6976e-023.8675e-070.4041imageNELAVL1;U2AF2;UPF1PSMD14T_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT
chr19:57220633-57222346:+ESCAEERENSG00000083844,ZNF264-0.42601.1124e-041.1141e-07-0.4046imageNELAVL1;U2AF2;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:57220633-57222346:+ESCAEERENSG00000086504,MRPL280.37739.6417e-042.6681e-090.4487imageNELAVL1;U2AF2;UPF1NAT_cells_CD4_memory_restingGSVA_HALLMARK_DNA_REPAIR
chr19:57220633-57222346:+OVEERENSG00000083844,ZNF264-0.39633.1626e-084.3500e-12-0.4010imageNELAVL1;U2AF2;UPF1NAT_cells_CD8GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr19:57220633-57222346:+OVEERENSG00000171222,SCAND10.37382.3468e-071.6812e-120.4081imageNELAVL1;UPF1NAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_DN
chr19:57220633-57222346:+OVEERENSG00000140990,NDUFB100.31054.1259e-054.1914e-120.4013imageNELAVL1;U2AF2;UPF1NAT_cells_CD8GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr19:57220633-57222346:+OVEERENSG00000137038,TMEM2610.22865.2829e-039.4774e-130.4123imageNELAVL1;U2AF2;UPF1NAT_cells_CD8GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr19:57220633-57222346:+THYMEERENSG00000104522,TSTA30.44631.6925e-053.7395e-090.5195imageNELAVL1;U2AF2;UPF1TSTA3T_cells_CD4_memory_activatedGSVA_HALLMARK_UV_RESPONSE_DN
chr19:57220633-57222346:+THYMEERENSG00000131849,ZNF132-0.45823.2733e-054.0369e-07-0.4553imageNELAVL1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION

More results



Top

4. Enriched editing regions and immune related splicing for ZNF264


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:57220633-57222346:+
BLCAEERIRENSG00000177479.15chr348924717:48924971:48927461:48927725-0.32307.3492e-101.5010e-12-0.4049imageNELAVL1;U2AF2;UPF1NAT_cells_CD4_memory_activatedGSVA_HALLMARK_UV_RESPONSE_UP
chr19:57220633-57222346:+
BLCAEERIRENSG00000123737.8chr4121813754:121814047:121816143:121816194-0.30849.4070e-092.2009e-12-0.4008imageNELAVL1;U2AF2;UPF1NAT_cells_CD4_memory_activatedGSVA_HALLMARK_UV_RESPONSE_UP
chr19:57220633-57222346:+
BLCAEERIRENSG00000125901.5chr203046613:3046900:3047734:3048254-0.40715.4895e-134.5370e-15-0.4058imageNELAVL1;U2AF2;UPF1NAMacrophages_M1GSVA_HALLMARK_UV_RESPONSE_UP
chr19:57220633-57222346:+
BLCAEERIRENSG00000106400.7chr7101218180:101221796:101222603:101222774-0.39541.3360e-124.6660e-15-0.4073imageNELAVL1;U2AF2;UPF1NAMacrophages_M1GSVA_HALLMARK_UV_RESPONSE_UP
chr19:57220633-57222346:+
BLCAEERIRENSG00000113240.8chr5178616877:178616948:178617343:178617434-0.36522.6050e-121.4577e-15-0.4390imageNELAVL1;U2AF2;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr19:57220633-57222346:+
BLCAEERIRENSG00000142046.10chr1941382771:41382921:41383714:41383722-0.35204.4667e-124.6405e-13-0.4245imageNELAVL1;U2AF2;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chr19:57220633-57222346:+
BLCAEERIRENSG00000113240.8chr5178616881:178617434:178618555:178618778-0.35011.1325e-119.8033e-14-0.4200imageNELAVL1;U2AF2;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_UP
chr19:57220633-57222346:+
BLCAEERIRENSG00000013441.11chr2200859679:200859746:200860124:200860212-0.38741.9196e-111.3327e-15-0.4040imageNELAVL1;U2AF2;UPF1NAT_cells_CD4_naiveGSVA_HALLMARK_UV_RESPONSE_UP
chr19:57220633-57222346:+
ESCAEERIRENSG00000165275.5chr937773305:37776405:37777600:37778022-0.37434.1353e-033.4061e-07-0.4008imageNELAVL1;U2AF2;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MTORC1_SIGNALING
chr19:57220633-57222346:+
ESCAEERIRENSG00000116396.9chr1110225974:110232597:110232910:110234044-0.32101.8368e-022.7510e-07-0.4127imageNELAVL1;U2AF2;UPF1NAMacrophages_M1GSVA_HALLMARK_BILE_ACID_METABOLISM

More results



Top

5. Enriched editing regions and immune infiltration for ZNF264


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:57220633-57222346:+ACCEERT_cells_regulatory_(Tregs)3.9224e-02-0.2470image
chr19:57220633-57222346:+BLCAEERT_cells_regulatory_(Tregs)1.0992e-04-0.2011image
ENSG00000083844.9,ZNF264BLCAEAGT_cells_CD4_naive5.1836e-04-0.1759image
chr19:57217394-57218014:+BRCAEERDendritic_cells_activated2.8031e-02-0.1342image
chr19:57220633-57222346:+BRCAEERT_cells_CD4_memory_activated1.2989e-070.1630image
ENSG00000083844.9,ZNF264BRCAEAGB_cells_naive1.4833e-05-0.1320image
chr19:57216048-57216321:+CESCEERT_cells_CD4_naive1.8663e-030.2171image
chr19:57220633-57222346:+CESCEERT_cells_CD4_memory_activated4.5873e-020.1239image
ENSG00000083844.9,ZNF264CESCEAGT_cells_CD4_memory_activated3.8524e-030.1740image
chr19:57216048-57216321:+CHOLEERT_cells_CD4_memory_resting4.3763e-020.4065image
ENSG00000083844.9,ZNF264CHOLEAGPlasma_cells4.7307e-040.5744image
chr19:57216048-57216321:+COADEERDendritic_cells_activated1.1181e-050.5225image
ENSG00000083844.9,ZNF264COADEAGDendritic_cells_resting2.1631e-02-0.1832image
ENSG00000083844.9,ZNF264DLBCEAGEosinophils2.8744e-020.3460image
chr19:57220633-57222346:+ESCAEERT_cells_regulatory_(Tregs)1.3863e-03-0.2507image
ENSG00000083844.9,ZNF264ESCAEAGT_cells_regulatory_(Tregs)1.6567e-03-0.2460image
chr19:57214334-57214663:+GBMEERT_cells_CD4_memory_activated4.0878e-020.1971image
ENSG00000083844.9,ZNF264GBMEAGMonocytes2.7821e-020.1762image
chr19:57214334-57214663:+HNSCEERNeutrophils8.2759e-03-0.1548image
chr19:57220633-57222346:+HNSCEERNK_cells_resting3.3884e-030.1460image
ENSG00000083844.9,ZNF264HNSCEAGT_cells_CD4_memory_resting9.0859e-04-0.1543image
chr19:57216048-57216321:+KICHEERT_cells_CD4_memory_activated4.4352e-020.3012image
ENSG00000083844.9,ZNF264KICHEAGEosinophils3.4610e-040.4367image
chr19:57220633-57222346:+KIRCEERT_cells_regulatory_(Tregs)1.0427e-02-0.1337image
ENSG00000083844.9,ZNF264KIRCEAGT_cells_CD4_memory_activated5.5090e-030.1425image
chr19:57214334-57214663:+KIRPEERT_cells_follicular_helper1.3919e-02-0.2053image
chr19:57220633-57222346:+KIRPEERT_cells_CD4_memory_activated6.5573e-030.1698image
ENSG00000083844.9,ZNF264KIRPEAGMacrophages_M03.9838e-020.1256image
chr19:57214334-57214663:+LGGEERT_cells_follicular_helper4.2200e-030.1470image
ENSG00000083844.9,ZNF264LGGEAGT_cells_CD4_memory_resting4.5204e-03-0.1252image
chr19:57216048-57216321:+LIHCEERT_cells_gamma_delta1.3531e-020.2415image
chr19:57220633-57222346:+LIHCEERB_cells_memory3.4186e-02-0.1459image
ENSG00000083844.9,ZNF264LIHCEAGEosinophils3.5498e-02-0.1350image
chr19:57220633-57222346:+LUADEERT_cells_CD4_memory_activated1.8932e-040.1825image
ENSG00000083844.9,ZNF264LUADEAGT_cells_CD4_memory_activated1.5754e-020.1131image
chr19:57214334-57214663:+LUSCEERPlasma_cells1.2381e-020.1403image
chr19:57216048-57216321:+LUSCEERT_cells_CD4_memory_activated4.6173e-040.1926image
chr19:57220633-57222346:+LUSCEERT_cells_CD4_naive2.6528e-02-0.1131image
ENSG00000083844.9,ZNF264LUSCEAGT_cells_gamma_delta4.1897e-02-0.0971image
chr19:57214334-57214663:+MESOEERMast_cells_resting2.4532e-02-0.3277image
chr19:57214334-57214663:+OVEERT_cells_regulatory_(Tregs)1.0673e-030.2303image
chr19:57217394-57218014:+OVEERT_cells_CD82.8561e-020.2180image
chr19:57220633-57222346:+OVEERT_cells_CD81.2987e-020.1494image
ENSG00000083844.9,ZNF264OVEAGT_cells_CD89.9757e-030.1529image
chr19:57214334-57214663:+PAADEERB_cells_naive6.6419e-03-0.2646image
chr19:57216048-57216321:+PAADEERT_cells_gamma_delta1.1206e-030.3001image
ENSG00000083844.9,ZNF264PAADEAGB_cells_naive4.3691e-02-0.1554image
chr19:57214334-57214663:+PCPGEERNeutrophils3.3062e-02-0.2201image
chr19:57220633-57222346:+PCPGEERB_cells_naive3.9967e-030.2141image
ENSG00000083844.9,ZNF264PCPGEAGB_cells_naive7.9633e-040.2471image
chr19:57220633-57222346:+PRADEERT_cells_CD4_memory_resting2.8740e-030.1347image
ENSG00000083844.9,ZNF264PRADEAGDendritic_cells_resting6.1862e-03-0.1229image
ENSG00000083844.9,ZNF264READEAGB_cells_naive5.8699e-050.5367image
chr19:57214334-57214663:+SARCEERPlasma_cells3.4703e-020.1868image
chr19:57220633-57222346:+SARCEERDendritic_cells_resting1.7855e-02-0.1585image
ENSG00000083844.9,ZNF264SARCEAGNK_cells_resting1.2336e-02-0.1613image
ENSG00000083844.9,ZNF264SKCMEAGT_cells_CD84.1806e-020.0994image
chr19:57214334-57214663:+STADEERB_cells_memory3.6049e-02-0.1363image
chr19:57217394-57218014:+STADEERT_cells_CD4_memory_activated3.0483e-050.2696image
chr19:57220633-57222346:+STADEERDendritic_cells_activated7.8187e-040.1811image
ENSG00000083844.9,ZNF264STADEAGT_cells_CD4_memory_activated6.7834e-030.1449image
chr19:57214334-57214663:+TGCTEERB_cells_naive4.2410e-020.2169image
chr19:57220633-57222346:+TGCTEERT_cells_CD4_naive2.8907e-050.3908image
chr19:57220633-57222346:+THCAEERDendritic_cells_activated1.5111e-060.2140image
ENSG00000083844.9,ZNF264THCAEAGT_cells_regulatory_(Tregs)1.6369e-040.1676image
chr19:57214334-57214663:+THYMEERT_cells_CD4_naive8.8893e-04-0.4688image
chr19:57216048-57216321:+THYMEERT_cells_CD4_naive2.5622e-02-0.2594image
chr19:57220633-57222346:+THYMEERT_cells_CD4_memory_activated3.9953e-090.5186image
ENSG00000083844.9,ZNF264THYMEAGT_cells_CD4_memory_activated6.4209e-120.5896image
chr19:57220633-57222346:+UCECEERDendritic_cells_resting3.8918e-02-0.1705image


Top

6. Enriched editing regions and immune gene sets for ZNF264


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
ENSG00000083844.9,ZNF264STADEAG9.1750e-03image4.0398e-02-0.1099image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr19:57220633-57222346:+BLCAEER1.4441e-070.27112.1111e-020.12071.9999e-070.26811.7486e-120.3581image
chr19:57220633-57222346:+BRCAEER4.3160e-210.28673.9940e-150.24051.7140e-080.17391.3921e-030.0991image
ENSG00000083844.9,ZNF264BRCAEAG1.4082e-090.18381.3352e-030.09802.7959e-030.09145.8490e-030.0842image
chr19:57220633-57222346:+ESCAEER1.0764e-050.34022.2981e-020.17973.0932e-050.32301.6760e-020.1889image
chr19:57220633-57222346:+LUADEER8.2980e-080.25975.3543e-080.26342.1504e-050.20722.4752e-060.2291image
ENSG00000083844.9,ZNF264SARCEAG1.7611e-02-0.15313.0787e-03-0.19032.7442e-03-0.19255.5181e-030.1786image
chr19:57217394-57218014:+STADEER9.0171e-070.31521.6615e-040.24431.4208e-050.28023.2003e-020.1405image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr19:57220633-57222346:+ACCGSVA_HALLMARK_HYPOXIAEER4.6127e-030.3348image
ENSG00000083844.9,ZNF264ACCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG8.2136e-030.3092image
ENSG00000083844.9,ZNF264BLCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG5.9099e-080.2716image
chr19:57220633-57222346:+BLCAGSVA_HALLMARK_HYPOXIAEER1.7486e-120.3581image
chr19:57217394-57218014:+BRCAGSVA_HALLMARK_PROTEIN_SECRETIONEER3.6153e-02-0.1281image
ENSG00000083844.9,ZNF264BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.1363e-110.2056image
chr19:57220633-57222346:+BRCAGSVA_HALLMARK_MTORC1_SIGNALINGEER3.9280e-180.2649image
chr19:57216048-57216321:+CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.3700e-020.1728image
ENSG00000083844.9,ZNF264CESCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.1105e-050.2539image
chr19:57220633-57222346:+CESCGSVA_HALLMARK_GLYCOLYSISEER2.5948e-030.1861image
ENSG00000083844.9,ZNF264CHOLGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG3.3476e-020.3711image
chr19:57216048-57216321:+COADGSVA_HALLMARK_P53_PATHWAYEER4.6478e-02-0.2518image
ENSG00000083844.9,ZNF264COADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.9203e-02-0.1741image
chr19:57220633-57222346:+ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEER9.4012e-05-0.3038image
ENSG00000083844.9,ZNF264ESCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG4.9755e-050.3140image
ENSG00000083844.9,ZNF264GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.0952e-030.2590image
chr19:57214334-57214663:+GBMGSVA_HALLMARK_MITOTIC_SPINDLEEER5.5025e-03-0.2654image
chr19:57214334-57214663:+HNSCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.9088e-07-0.3001image
ENSG00000083844.9,ZNF264HNSCGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.5222e-08-0.2564image
chr19:57220633-57222346:+HNSCGSVA_HALLMARK_HYPOXIAEER4.4111e-050.2025image
ENSG00000083844.9,ZNF264KICHGSVA_HALLMARK_HYPOXIAEAG5.5423e-030.3455image
chr19:57220633-57222346:+KIRCGSVA_HALLMARK_SPERMATOGENESISEER2.8790e-030.1554image
ENSG00000083844.9,ZNF264KIRCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG3.0475e-05-0.2127image
ENSG00000083844.9,ZNF264KIRPGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.6025e-03-0.1918image
chr19:57216048-57216321:+KIRPGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.8966e-03-0.2306image
chr19:57214334-57214663:+KIRPGSVA_HALLMARK_UV_RESPONSE_DNEER3.0669e-03-0.2460image
chr19:57220633-57222346:+KIRPGSVA_HALLMARK_GLYCOLYSISEER1.1559e-050.2708image
ENSG00000083844.9,ZNF264LAMLGSVA_HALLMARK_NOTCH_SIGNALINGEAG9.4200e-030.2261image
ENSG00000083844.9,ZNF264LGGGSVA_HALLMARK_MITOTIC_SPINDLEEAG8.3362e-07-0.2155image
chr19:57214334-57214663:+LGGGSVA_HALLMARK_MITOTIC_SPINDLEEER1.6321e-05-0.2200image
chr19:57220633-57222346:+LIHCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.7179e-030.2054image
chr19:57216048-57216321:+LIHCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER5.6012e-030.2698image
ENSG00000083844.9,ZNF264LIHCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG9.5975e-040.2105image
ENSG00000083844.9,ZNF264LUADGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.6882e-050.1922image
chr19:57220633-57222346:+LUADGSVA_HALLMARK_MTORC1_SIGNALINGEER1.5718e-130.3521image
ENSG00000083844.9,ZNF264LUSCGSVA_HALLMARK_HEME_METABOLISMEAG4.6532e-03-0.1348image
chr19:57214334-57214663:+LUSCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER2.7590e-02-0.1238image
chr19:57216048-57216321:+LUSCGSVA_HALLMARK_MYC_TARGETS_V1EER3.8925e-040.1950image
chr19:57220633-57222346:+LUSCGSVA_HALLMARK_E2F_TARGETSEER9.5501e-050.1975image
chr19:57220633-57222346:+MESOGSVA_HALLMARK_UV_RESPONSE_DNEER1.0964e-020.2884image
ENSG00000083844.9,ZNF264MESOGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG4.0409e-02-0.2297image
chr19:57214334-57214663:+OVGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER4.8473e-03-0.1989image
chr19:57220633-57222346:+OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER7.5850e-070.2925image
chr19:57217394-57218014:+OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER6.5688e-060.4317image
ENSG00000083844.9,ZNF264OVGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG9.6682e-08-0.3105image
chr19:57216048-57216321:+PAADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER2.4625e-030.2798image
ENSG00000083844.9,ZNF264PAADGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG4.3056e-040.2678image
chr19:57214334-57214663:+PAADGSVA_HALLMARK_P53_PATHWAYEER3.2761e-020.2096image
chr19:57220633-57222346:+PAADGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER8.9214e-050.2994image
chr19:57220633-57222346:+PCPGGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER3.9789e-040.2619image
ENSG00000083844.9,ZNF264PCPGGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG5.5440e-040.2542image
chr19:57214334-57214663:+PCPGGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.9754e-020.2401image
chr19:57220633-57222346:+PRADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER5.1938e-030.1263image
ENSG00000083844.9,ZNF264PRADGSVA_HALLMARK_DNA_REPAIREAG2.3961e-030.1362image
chr19:57220633-57222346:+SARCGSVA_HALLMARK_HYPOXIAEER1.6018e-030.2101image
ENSG00000083844.9,ZNF264SARCGSVA_HALLMARK_COAGULATIONEAG1.7736e-050.2732image
chr19:57214334-57214663:+SARCGSVA_HALLMARK_HYPOXIAEER7.0298e-030.2372image
ENSG00000083844.9,ZNF264SKCMGSVA_HALLMARK_GLYCOLYSISEAG3.2693e-030.1432image
chr19:57220633-57222346:+SKCMGSVA_HALLMARK_MTORC1_SIGNALINGEER9.2978e-040.1696image
ENSG00000083844.9,ZNF264STADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG6.5435e-08-0.2847image
chr19:57214334-57214663:+STADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER2.0091e-030.1997image
chr19:57220633-57222346:+STADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.1265e-05-0.2280image
chr19:57217394-57218014:+STADGSVA_HALLMARK_MTORC1_SIGNALINGEER2.2043e-070.3316image
chr19:57214334-57214663:+TGCTGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.4995e-02-0.2251image
chr19:57220633-57222346:+TGCTGSVA_HALLMARK_GLYCOLYSISEER4.4373e-030.2718image
ENSG00000083844.9,ZNF264TGCTGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG4.1811e-03-0.2459image
ENSG00000083844.9,ZNF264THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG3.2251e-110.2908image
chr19:57220633-57222346:+THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER1.3106e-090.2680image
ENSG00000083844.9,ZNF264THYMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG7.6501e-050.3633image
chr19:57220633-57222346:+THYMGSVA_HALLMARK_GLYCOLYSISEER3.0446e-040.3337image
chr19:57216048-57216321:+THYMGSVA_HALLMARK_ANDROGEN_RESPONSEEER2.5000e-04-0.4135image
chr19:57214334-57214663:+THYMGSVA_HALLMARK_MITOTIC_SPINDLEEER2.3886e-03-0.4326image
chr19:57220633-57222346:+UCECGSVA_HALLMARK_E2F_TARGETSEER3.2518e-020.1765image
ENSG00000083844.9,ZNF264UCECGSVA_HALLMARK_COAGULATIONEAG2.4533e-020.1818image
ENSG00000083844.9,ZNF264UCSGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG1.5676e-020.3401image
ENSG00000083844.9,ZNF264UVMGSVA_HALLMARK_P53_PATHWAYEAG2.2492e-020.2806image


Top

7. Enriched editing regions and drugs for ZNF264


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr19:57220633-57222346:+ACCAICAREER6.6907e-03-0.3213image
ENSG00000083844.9,ZNF264ACCAICAREAG1.1633e-03-0.3752image
chr19:57220633-57222346:+BLCAKU.55933EER3.3213e-13-0.3688image
ENSG00000083844.9,ZNF264BLCACMKEAG5.0729e-06-0.2298image
chr19:57217394-57218014:+BRCAATRAEER1.9424e-020.1432image
ENSG00000083844.9,ZNF264BRCACCT007093EAG3.7303e-100.1901image
chr19:57220633-57222346:+BRCACCT007093EER1.3412e-130.2270image
ENSG00000083844.9,ZNF264CESCCEP.701EAG8.4294e-04-0.2005image
chr19:57216048-57216321:+CESCErlotinibEER2.3002e-02-0.1595image
ENSG00000083844.9,ZNF264CHOLBleomycinEAG4.3592e-020.3535image
chr19:57216048-57216321:+CHOLAZ628EER3.9963e-02-0.4134image
chr19:57216048-57216321:+COADBMS.509744EER9.6302e-040.4060image
ENSG00000083844.9,ZNF264COADBMS.708163EAG2.8990e-02-0.1743image
ENSG00000083844.9,ZNF264ESCAKU.55933EAG4.6903e-04-0.2734image
chr19:57220633-57222346:+ESCABI.D1870EER1.2234e-04-0.2991image
ENSG00000083844.9,ZNF264GBMLapatinibEAG5.9712e-04-0.2719image
chr19:57214334-57214663:+GBMGDC.0449EER3.5918e-03-0.2779image
chr19:57214334-57214663:+HNSCAZD6482EER2.2836e-030.1785image
chr19:57220633-57222346:+HNSCATRAEER2.8640e-030.1485image
ENSG00000083844.9,ZNF264HNSCDocetaxelEAG4.3686e-08-0.2521image
chr19:57216048-57216321:+KICHBIBW2992EER2.1927e-030.4450image
chr19:57220633-57222346:+KIRCAZD.2281EER2.0409e-04-0.1932image
ENSG00000083844.9,ZNF264KIRCAZD6244EAG4.9564e-11-0.3296image
ENSG00000083844.9,ZNF264KIRPDoxorubicinEAG7.8555e-040.2039image
chr19:57214334-57214663:+KIRPDMOGEER1.7650e-040.3086image
chr19:57216048-57216321:+KIRPBryostatin.1EER1.6575e-02-0.1789image
chr19:57220633-57222346:+KIRPA.443654EER1.8892e-040.2317image
ENSG00000083844.9,ZNF264LAMLATRAEAG1.4468e-020.2132image
chr19:57214334-57214663:+LGGEHT.1864EER3.9008e-04-0.1817image
ENSG00000083844.9,ZNF264LGGMidostaurinEAG3.6883e-060.2027image
chr19:57220633-57222346:+LIHCA.770041EER3.3071e-03-0.2105image
chr19:57216048-57216321:+LIHCIPA.3EER6.2376e-060.4268image
ENSG00000083844.9,ZNF264LIHCA.770041EAG1.5592e-03-0.2116image
chr19:57220633-57222346:+LUADCHIR.99021EER1.3638e-050.2125image
ENSG00000083844.9,ZNF264LUADBMS.708163EAG3.3116e-04-0.1675image
chr19:57220633-57222346:+LUSCAS601245EER3.9328e-040.1798image
chr19:57214334-57214663:+LUSCABT.263EER2.5976e-030.1686image
ENSG00000083844.9,ZNF264LUSCGefitinibEAG2.7449e-04-0.1730image
chr19:57216048-57216321:+LUSCLFM.A13EER2.4775e-050.2309image
chr19:57220633-57222346:+MESOImatinibEER4.1371e-04-0.3925image
ENSG00000083844.9,ZNF264MESOAICAREAG1.3456e-02-0.2753image
chr19:57214334-57214663:+MESOAZD.2281EER1.9581e-02-0.3395image
chr19:57220633-57222346:+OVEmbelinEER1.5955e-090.3531image
ENSG00000083844.9,ZNF264OVEmbelinEAG1.2357e-120.4056image
chr19:57217394-57218014:+OVImatinibEER9.1586e-050.3793image
chr19:57214334-57214663:+OVAZD6244EER2.2246e-05-0.2957image
chr19:57220633-57222346:+PAADAxitinibEER4.9360e-030.2185image
chr19:57214334-57214663:+PAADATRAEER5.8115e-030.2700image
ENSG00000083844.9,ZNF264PAADAxitinibEAG4.9454e-030.2165image
chr19:57220633-57222346:+PCPGGSK.650394EER3.4258e-040.2647image
ENSG00000083844.9,ZNF264PCPGGSK.650394EAG1.1526e-040.2827image
chr19:57214334-57214663:+PCPGEmbelinEER1.2520e-030.3280image
chr19:57220633-57222346:+PRADCCT018159EER2.6914e-050.1888image
ENSG00000083844.9,ZNF264PRADCCT018159EAG8.2049e-040.1499image
ENSG00000083844.9,ZNF264SARCBI.D1870EAG7.0441e-050.2537image
chr19:57214334-57214663:+SARCGNF.2EER2.8468e-03-0.2617image
chr19:57220633-57222346:+SARCCMKEER2.3274e-030.2029image
ENSG00000083844.9,ZNF264SKCMDoxorubicinEAG2.8141e-030.1454image
chr19:57220633-57222346:+SKCMGefitinibEER2.4125e-030.1558image
ENSG00000083844.9,ZNF264STADImatinibEAG2.1191e-040.1973image
chr19:57214334-57214663:+STADATRAEER7.8285e-030.1724image
chr19:57220633-57222346:+STADGefitinibEER2.4432e-04-0.1980image
chr19:57217394-57218014:+STADBX.795EER4.6632e-040.2275image
chr19:57214334-57214663:+TGCTBortezomibEER2.5038e-020.2388image
chr19:57220633-57222346:+TGCTA.443654EER7.8617e-04-0.3183image
ENSG00000083844.9,ZNF264TGCTGDC0941EAG2.4069e-03-0.2601image
chr19:57220633-57222346:+THCACI.1040EER7.4518e-08-0.2387image
ENSG00000083844.9,ZNF264THCACI.1040EAG2.9430e-13-0.3183image
chr19:57220633-57222346:+THYMA.770041EER4.8169e-07-0.4526image
chr19:57216048-57216321:+THYMDMOGEER1.6973e-040.4236image
ENSG00000083844.9,ZNF264THYMAZD6244EAG5.7202e-09-0.5142image
chr19:57214334-57214663:+THYMATRAEER1.7908e-030.4436image
chr19:57220633-57222346:+UCECJNK.Inhibitor.VIIIEER1.6587e-04-0.3057image
ENSG00000083844.9,ZNF264UCECGefitinibEAG2.3186e-02-0.1835image
ENSG00000083844.9,ZNF264UCSJNK.9LEAG4.5386e-020.2843image
ENSG00000083844.9,ZNF264UVMJNK.9LEAG1.7320e-02-0.2921image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType